Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2000
11/16/2000WO2000067735A2 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000067733A2 Medicament for treating human infertility
11/16/2000WO2000067732A2 Pharmaceutical composition, containing an antimycotic, polydocanol and salicylic acid
11/16/2000WO2000067731A2 Medicinal substance utilization for preventing nitrate tolerance
11/16/2000WO2000067730A1 Drug delivery device
11/16/2000WO2000067729A1 Regimen and kit for amelioration of premature ejaculation
11/16/2000WO2000067708A2 Oral steroidal hormone compositions and methods of use
11/16/2000WO2000067699A2 Pharmaceutical compositions for treating malaria
11/16/2000WO2000067698A2 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation
11/16/2000WO2000067697A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000WO2000067626A2 Oat extracts: refining, compositions and methods of use
11/16/2000WO2000067592A1 Methods for lowering viscosity of glucomannan compositions
11/16/2000WO2000067589A1 Method for manufacturing rumen bypass feed supplement
11/16/2000WO2000067579A1 Stabilization of isothiazolone
11/16/2000WO2000056336A3 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
11/16/2000WO2000053228A3 Use of niaouli essential oil as transdermal permeation enhancer
11/16/2000WO2000048996A3 β-ALANINE DERIVATIVES
11/16/2000WO2000043501A3 Ribozymes directed against the catalytic subunit of the human telomerase (htert)
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000041717A3 Chorionic gonadotropin dna vaccines and methods
11/16/2000WO2000041669A3 Benzimidazole vascular damaging agents
11/16/2000WO2000041469A3 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
11/16/2000WO2000040242A3 Preparation of a composition against hepatitis b-, hi-, paramyxo- and orthomyxoviruses
11/16/2000WO2000039287A3 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides and uses thereof
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000038663A3 Ep4 receptor agonists for treatment of dry eye
11/16/2000WO2000038625A3 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants
11/16/2000WO2000038536A3 Inhibitors of the bitter taste response
11/16/2000WO2000037613A3 Human akt-3
11/16/2000WO2000037059A3 Compositions and methods to inactivate n-type calcium channels
11/16/2000WO2000037057A3 Novel formulations comprising lipid-regulating agents
11/16/2000WO2000035432A3 Improved viscoelastic compositions and methods of use
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000034285A3 Substituted benzofuranoindoles and indenoindoles as novel potassium channel openers
11/16/2000WO2000033874B1 Boron neutron capture therapy using pre-targeting methods
11/16/2000WO2000033825A3 Compositions and methods for amelioration of human female sexual dysfunction
11/16/2000WO2000032656A3 Polymers containing spirobicyclic ammonium moieties and use thereof
11/16/2000WO2000032186A3 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
11/16/2000WO2000032180A3 Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituted indolealkanoic acids
11/16/2000WO2000032174A3 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide
11/16/2000WO2000030653A3 Use of phosphonoformic acid derivatives for treating infections
11/16/2000WO2000029015A3 INFLUENCING OF ANGIGENESIS USING CD66a
11/16/2000WO2000027887A3 Cross-linked hyaluronic acids and medical uses thereof
11/16/2000WO2000027846A3 Crf receptor antagonists and methods relating thereto
11/16/2000WO2000026370A3 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/16/2000WO2000026224A3 Novel macrolide antibiotics
11/16/2000WO2000025721A3 Sodium salt of 3-(4-cinnamyl-1-piperazinyl)imino-methyl rifamycin sv and process of preparation
11/16/2000WO2000023061A3 Irrigation solution and method for inhibition of pain and inflammation
11/16/2000WO2000020556A3 Zinc finger-reactive antimicrobial compounds
11/16/2000WO2000020448A3 Nlk1 -interacting proteins
11/16/2000WO2000020358A3 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
11/16/2000WO2000018389A3 USE OF A β2 ADRENERGIC RECEPTOR AGONIST IN THE TREATMENT OF CARDIOVASCULAR DISEASE
11/16/2000WO2000018365A3 Fast dissolving orally consumable films
11/16/2000WO2000018316A3 Sustained release, and comfortable ophthalmic composition and method for ocular therapy
11/16/2000WO2000015634A3 Hiv protease inhibitors
11/16/2000WO2000009103A3 N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders
11/16/2000WO2000006138A3 Use of moclobemide for treating pain and other diseases
11/16/2000WO2000000158A3 Alkylamines and their precursors as specific modulators of human gamma-delta t cell function
11/16/2000WO2000000157A3 Use of tempo and tempo derivatives for inducing cell death
11/16/2000DE19921887A1 Synergistic ectoparasiticide combination for use in human or veterinary medicine, comprising cyclic depsipeptide and piperazine compound as potentiating agent
11/16/2000DE19921693A1 Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000DE19921101A1 Neue spirocyclische Verbindungen, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung hyperproliferativer Erkrankungen New spirocyclic compounds, processes for their preparation and their use for the treatment of hyperproliferative diseases
11/16/2000DE19920775A1 Arzneistoffverwendung zur Vermeidung von Nitrattoleranz Drug use in the prevention of nitrate tolerance
11/16/2000DE19920491A1 Medikament zur Therapie der männlichen Infertilität Drug for the treatment of male infertility
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000DE19907895A1 Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können Use of R-arylpropionic acids for producing drugs for treating diseases in humans and animals, which can be influenced therapeutically by inhibiting the activation of NF-kB
11/16/2000DE10021266A1 Hergestellte Artikel mit Phosphodiesterase-Inhibitor Produced with Article phosphodiesterase inhibitor
11/16/2000CA2373851A1 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000CA2373759A1 Serine proteases
11/16/2000CA2373672A1 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation
11/16/2000CA2373637A1 Treatment of bone cancer
11/16/2000CA2373618A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
11/16/2000CA2373447A1 Permeabilizing biofilms
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373442A1 14.beta.-h-sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments
11/16/2000CA2373348A1 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
11/16/2000CA2373193A1 Process for preparing (1r,2s,4r) -(-)-2-[(2'- {n,n-dimethylamino} -ethoxy)] -2-[phenyl] -1,7,7-tri- [methyl] -bicyclo [2.2.1] heptane and pharmaceutically acceptable acid additionsalts thereof
11/16/2000CA2373178A1 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
11/16/2000CA2373173A1 Aromatic amides
11/16/2000CA2373121A1 Vector-mediated delivery of integrating transposon sequences
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2373073A1 Cyclic compounds and uses thereof
11/16/2000CA2373052A1 Novel, specific inhibitors of acute and chronic inflammation
11/16/2000CA2373050A1 Cardioprotective composition and uses thereof
11/16/2000CA2373039A1 Neuroprotective composition and uses thereof
11/16/2000CA2373015A1 Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
11/16/2000CA2373010A1 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
11/16/2000CA2372961A1 Halo- or hydroxy-substituted nocathiacin antibiotics
11/16/2000CA2372881A1 Novel nucleic acids and proteins with p53 activity and altered tetramerization domains
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372812A1 Stabilization of isothiazolone
11/16/2000CA2372782A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2372663A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2372649A1 Methods for lowering viscosity of glucomannan compositions
11/16/2000CA2372496A1 Aryl amidines, compositions containing such compounds and methods of use
11/16/2000CA2372492A1 Cyclic amidines useful as nmda nr2b antagonists
11/16/2000CA2372461A1 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
1 ... 6208 6209 6210 6211 6212 6213 6214 6215 6216 6217 6218 6219 6220 6221 6222 6223 6224 6225 6226 6227 6228 ... 7860